Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Understanding walking activity in multiple sclerosis: step count, walking intensity and uninterrupted walking activity duration related to degree of disability.
Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3.
Biochemical manifestations of the nervous tissue degradation after the blood-brain barrier opening or water intoxication in rats.
A rare case of SPG11 mutation with multiple sclerosis.
Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial.
The relationship between static posturography measures and specific cognitive domains in individuals with multiple sclerosis.
All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary.
Leptin and other adipokines in EAE and MS
Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling.
Determinants of High Cost in Multiple Sclerosis Patients: A Claims and Chart Review Study.
The Efficacy of Functional Electrical Stimulation of the Abdominal Muscles in the Treatment of Chronic Constipation in Patients with Multiple Sclerosis: A Pilot Study.
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies.
Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study.
Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI).
Translational challenge models in support of efficacy studies: Neurobehavioral and cognitive changes induced by Transcranial Magnetic Stimulation in healthy volunteers.
Patterns of Use of Tests to Monitor Disease Activity Among Patients With Relapsing Remitting Multiple Sclerosis in the United States and Europe.
The role of geographical ecological studies in identifying diseases linked to UVB exposure and/or vitamin D.
Cognitive Impairment and Health Related Quality of Life in Relapsing Remitting Multiple Sclerosis.
Analysis of MMP2-1306C/T and TIMP2G-418C polymorphisms with relapsing remitting multiple sclerosis.
A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman.
Health Care Utilization and Costs of Medicaid Program Services for Patients Diagnosed with Multiple Sclerosis.
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »